ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed

ClearPoint Neuro, Inc.

2024-Q3 EPS reported -$0.50 revenue$23,619,000

Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).
Biologics & drug delivery revenue $4.4M (+27%); capital equipment revenue $0.8M (+133%).
Gross margin 60% vs 57% YoY; operating expenses $10M (up from $8.2M) on higher personnel and development costs.
Cash $21.6M; fully repaid $10M convertible note leaving no debt; operational cash burn cut 33% to $1.2M.
Activated 5 new centers in Q3 (19 YTD, ~3x historic rate); FY 2024 revenue outlook held at $30-33M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.